The aim of this study was to estimate the impact of antiphospholipid (aPL) antibodies on the
risk of incident thromboembolism (TE; arterial and venous) in children via meta-analysis of …

Background Antiphospholipid antibodies (aPL) have been extensively reported in children,
but investigations into thrombotic risks associated with aPL positivity in pediatric patients is …

Persistent antiphospholipid (aPL) antibodies are occasionally found in subjects without prior
history of thromboembolic events (TEs), raising the dilemma of whether to initiate or not a …

Background Patients with antiphospholipid antibodies (aPL) and thromboembolism (TE) are
at risk for recurrent TE. Few studies, however, distinguish patients based on the initial event …

Pediatric antiphospholipid syndrome (APS) is characterized by vascular thromboses and
multisystem involvement associated with persistently positive antiphospholipid antibodies …

Antiphospholipid antibodies (APAs) are considered risk factors in patients with
thromboembolic diseases. Although the incidence of such acquired coagulation …

Objectives The long-term prognosis of individuals fulfilling the laboratory criteria, but not
clinical criteria, of antiphospholipid syndrome (APS) has not been widely investigated. The …

Background. It is difficult to estimate the actual prevalence of antiphospholipid syndrome
(APS) in the paediatric population since there are no standardised criteria. We aimed to …

Antiphospholipid syndrome (APS) is a multisystem autoimmune condition characterized by
vascular thromboses associated with persistently positive antiphospholipid antibodies …

Laboratory evidence of antiphospholipid antibodies (APLA) in patients with a first episode of
venous thromboembolism (VTE) is often considered an indication for indefinite …